HR17031 injection + insulin glargine

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs

Conditions

Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs

Trial Timeline

Apr 30, 2024 → Sep 19, 2025

NCT ID

NCT06881264

About HR17031 injection + insulin glargine

HR17031 injection + insulin glargine is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs. The current trial status is completed. This product is registered under clinical trial identifier NCT06881264. Target conditions include Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs.

What happened to similar drugs?

9 of 20 similar drugs in Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs were approved

Approved (9) Terminated (3) Active (10)

✅BenralizumabAstraZenecaApproved

✅FluMist + inactivated influenza vaccineAstraZenecaApproved

✅Saizen® solution for injection (referred as Saizen®)MerckApproved

✅Tacrolimus/Sirolimus + Tacrolimus/MMF + Neoral/SirolimusRocheApproved

✅Aztreonam lysineGilead SciencesApproved

✅maraviroc + Raltegravir + Darunavir/ritonavirPfizerApproved

✅SabrilLundbeckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06871761	Phase 3	Completed	May 8, 2024	May 13, 2025	Adult Patients With Type 2 Diabetes
NCT06881264	Phase 3	Completed	Apr 30, 2024	Sep 19, 2025	Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs

Competing Products

20 competing products in Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs

See all competitors

Product	Company	Stage	Hype Score
BBP-398 + sotorasib	BridgeBio Pharma	Phase 1	18
Daridorexant + Placebo	Idorsia	Phase 1	23
SON-1010 (IL12-FHAB)	Sonnet BioTherapeutics	Phase 1	23
Somatropin	Eli Lilly	Phase 3	40
agenT-797	MiNK Therapeutics	Phase 1	19
Pegilodecakin	Eli Lilly	Phase 1	29
eFT226 + Sotorasib + Fulvestrant + Abemaciclib + Trastuzumab	eFFECTOR Therapeutics	Phase 1/2	29
Lazertinib(G001) + Lazertinib(G002)	Yuhan	Phase 1	29
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	27
DJ-927 + capecitabine	Daiichi Sankyo	Phase 1	29
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	35
Roxadustat	Astellas Pharma	Phase 1	29
ASP3325 + Placebo	Astellas Pharma	Phase 1	29
TRK-100STP	Astellas Pharma	Phase 1	29
Ensitrelvir	Shionogi	Phase 1	29
E6130 + Placebo	Eisai	Phase 1	29
E7389 + E7389 + E7389	Eisai	Phase 1	29
Eribulin Mesylate	Eisai	Phase 1	29
E2022 + E2022 + E2022 + E2022 + E2022	Eisai	Phase 1	29
Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride	Eisai	Phase 1	29